<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognosis of diffuse large B cell lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognosis of diffuse large B cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognosis of diffuse large B cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H17220637"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 25 percent of NHL cases [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The diagnostic category of DLBCL is morphologically, genetically, and biologically heterogeneous. Several distinct clinicopathologic entities are now considered separate diagnostic categories, and are discussed below or separately:</p><p class="bulletIndent1"><span class="glyph">●</span>T cell histiocyte rich large B cell lymphoma. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'T cell histiocyte-rich large B cell lymphoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary DLBCL of the mediastinum, also called primary mediastinal large B cell lymphoma. (See  <a class="medical medical_review" href="/d/html/4713.html" rel="external">"Primary mediastinal large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravascular lymphoma. (See  <a class="medical medical_review" href="/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphomatoid granulomatosis, an Epstein-Barr virus-positive large B cell lymphoma. (See  <a class="medical medical_review" href="/d/html/4324.html" rel="external">"Pulmonary lymphomatoid granulomatosis"</a> and  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Lymphomatoid granulomatosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ALK-positive large B cell lymphoma, associated with rearrangements in the <em>ALK</em> gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large B cell lymphoma associated with IRF4 rearrangement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epstein-Barr virus-positive DLBCL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DLBCL associated with chronic inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human herpesvirus 8 (HHV8)-positive DLBCLs, included primary effusion lymphoma and tissue based HHV8-positive tumors.</p><p></p><p>In addition, the 2016 revision of the World Health Organization (WHO) classification system describes categories of NHL, which have morphologic features that may resemble DLBCL [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>"High-grade B cell lymphoma." These tumors may have morphologic features that resemble DLBCL, Burkitt lymphoma (BL), or lymphoblastic lymphoma. Those with DLBCL or BL morphology are distinguished by the presence of <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> gene rearrangements, and are now classified as "high-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> gene rearrangements." These lymphomas are no longer considered a type of DLBCL, but many would have been previously described (eg, in the 2008 WHO classification) as "B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma," or "Burkitt-like" lymphoma, both of which were both eliminated from the 2016 revision. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Burkitt lymphoma'</a>.)</p><p></p><p class="bulletIndent1">Prognosis of high-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> gene rearrangements is described below. (See <a class="local">'Double hit lymphoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal grey zone lymphoma, previously known as B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Hodgkin lymphoma'</a>.)</p><p></p><p>The prognosis of nodal DLBCL will be reviewed here. The pathobiology, staging, diagnosis, and treatment of this disorder are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p></p><p>The prognosis of DLBCL that arises from transformation of a previously undiagnosed indolent lymphoid neoplasm is discussed separately. (See  <a class="medical medical_review" href="/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma", section on 'Prognosis and prognostic factors'</a> and  <a class="medical medical_review" href="/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="headingAnchor" id="H17219010"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>DLBCL is curable in approximately half of cases with current therapy, particularly in those who achieve a complete remission with first-line treatment. Tumor-extrinsic factors that contribute to outcome include age, socioeconomic conditions, comorbid conditions, performance status, and various clinical features [<a href="#rid3">3,4</a>].</p><p>Prognosis in DLBCL is highly associated with the International Prognostic Index (IPI) score, which was proposed in 1993 to assign prognosis to patients with aggressive non-Hodgkin lymphoma undergoing treatment with doxorubicin-containing chemotherapeutic regimens  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef104827" href="/d/graphic/104827.html" rel="external">figure 1</a>). These findings have been confirmed in many series of patients with DLBCL.</p><p>Other prognostic factors appear to either complement or outperform the IPI in patients with DLBCL, including tumor-intrinsic variables such as cell of origin and certain genetic abnormalities, as described below. (See <a class="local">'Molecular genetics'</a> below.)</p><p class="headingAnchor" id="H17219017"><span class="h1">INTERNATIONAL PROGNOSTIC INDEX</span><span class="headingEndMark"> — </span>The International Prognostic Index (IPI) and its variants are the main prognostic tools used in patients with DLBCL  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef104827" href="/d/graphic/104827.html" rel="external">figure 1</a>). These indices are significantly more accurate than standard staging criteria (which they incorporate) in predicting long-term survival.</p><p class="headingAnchor" id="H17219024"><span class="h2">Original IPI</span><span class="headingEndMark"> — </span>The IPI was developed to evaluate pretreatment features that predict survival in patients with aggressive non-Hodgkin lymphoma (eg, DLBCL) following treatment with doxorubicin-containing chemotherapy regimens [<a href="#rid5">5</a>]. The following factors correlate significantly with shorter overall survival (OS) or relapse-free survival (RFS):</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 years</p><p class="bulletIndent1"><span class="glyph">●</span>Serum lactate dehydrogenase (LDH) concentration greater than normal</p><p class="bulletIndent1"><span class="glyph">●</span>Eastern Cooperative Oncology Group (ECOG) performance status ≥2  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical stage III or IV  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;1 extranodal disease site</p><p></p><p>In this system, one point is given for each of the above characteristics present in the patient, for a total score ranging from zero to five, representing increasing degrees of risk  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef104827" href="/d/graphic/104827.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk – IPI score of zero or one</p><p class="bulletIndent1"><span class="glyph">●</span>Low-intermediate risk – IPI score of two</p><p class="bulletIndent1"><span class="glyph">●</span>High-intermediate risk – IPI score of three</p><p class="bulletIndent1"><span class="glyph">●</span>High risk – IPI score of four or five</p><p></p><p>When applied to an initial group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens that did not include <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, five-year OS rates for patients with scores of zero to one, two, three, and four to five were 73, 51, 43, and 26 percent, respectively.</p><p class="headingAnchor" id="H17219031"><span class="h2">Revised IPI</span><span class="headingEndMark"> — </span>The addition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to standard chemotherapy has resulted in improvements in OS rates in patients with CD20-positive tumors. Specifically, the combination of rituximab plus CHOP (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) or CHOP-like regimens is the most commonly employed treatment for DLBCL. The original IPI scoring system has been revalidated in this patient group [<a href="#rid6">6,7</a>].</p><p>An analysis of 1063 patients with aggressive B cell lymphoma who received <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> plus CHOP or CHOP-like chemotherapy in the context of three prospective trials reassessed the prognostic value of the original IPI [<a href="#rid6">6</a>]. At a median observation time exceeding 30 months, three-year estimates for event-free survival (EFS), progression-free survival (PFS), and OS as divided by IPI score were  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef104827" href="/d/graphic/104827.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>IPI score zero or one – Rates of 81, 87, and 91 percent, respectively</p><p class="bulletIndent1"><span class="glyph">●</span>IPI score two – Rates of 69, 75, and 81 percent, respectively</p><p class="bulletIndent1"><span class="glyph">●</span>IPI score three – Rates of 53, 59, and 65 percent, respectively</p><p class="bulletIndent1"><span class="glyph">●</span>IPI score four or five – Rates of 50, 56, and 59 percent, respectively</p><p></p><p>When patients from all three trials were analyzed as a single set, these four IPI groups differed significantly from each other in their estimates of EFS, PFS, and OS. These results support the use of the original IPI, rather than a revised IPI [<a href="#rid8">8,9</a>], for patient stratification and reporting of data from clinical trials of DLBCL using <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> therapy.</p><p>One potential limitation to the use of the original IPI in patients receiving <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> is that the difference in outcomes between patients in different IPI risk groups is relatively small. As described above, the estimated three-year survival rates among patients with the lowest and highest IPI scores were 91 and 59 percent, respectively. Despite this, the original IPI remains our preferred prognostic index for patients with DLBCL.</p><p class="headingAnchor" id="H22090600"><span class="h2">NCCN-IPI</span><span class="headingEndMark"> — </span>The National Comprehensive Cancer Network (NCCN)-IPI incorporates more detailed information about the clinical variables used in the original IPI (ie, age, LDH, ECOG performance status, stage, and extranodal disease). Specifically, age and LDH are considered as continuous rather than dichotomous variables, and the location of extranodal disease is used rather than the number of extranodal sites. These changes make the NCCN-IPI more cumbersome than the original IPI to apply at the bedside. For now, the original IPI remains our preferred prognostic index for patients with DLBCL.</p><p>Clinical variables and outcomes of 1650 patients with de novo DLBCL treated at seven NCCN cancer centers from 2000 to 2010 were used to create the NCCN-IPI, which awards points for each of the following variables [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age 41 to 60 years – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60 to 75 years – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;75 years – 3 points</p><p class="bulletIndent1"><span class="glyph">●</span>LDH ratio &gt;1 to 3 – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>LDH ratio &gt;3 – 2 points</p><p class="bulletIndent1"><span class="glyph">●</span>ECOG PS ≥2 – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Ann Arbor stage III to IV – 1 point</p><p class="bulletIndent1"><span class="glyph">●</span>Extranodal disease involving the bone marrow, central nervous system, liver/gastrointestinal tract, or lung – 1 point</p><p></p><p>The LDH variable is the ratio of the patient's LDH level to the upper limit of normal at the institution. The NCCN-IPI is the sum of these points. When applied to a separate cohort of 1138 patients in a registry from the British Columbia Cancer Agency treated with R-CHOP with curative intent since 2001, the NCCN-IPI was able to stratify patients into four risk groups with significantly different OS and PFS at five years:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk – 0 to 1 points (12 percent); OS 96 percent; PFS 94 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Low-intermediate risk – 2 to 3 points (37 percent); OS 77 percent; PFS 72 percent</p><p class="bulletIndent1"><span class="glyph">●</span>High-intermediate risk – 4 to 5 points (37 percent); OS 56 percent; PFS 54 percent</p><p class="bulletIndent1"><span class="glyph">●</span>High risk – ≥6 points (14 percent); OS 38 percent; PFS 35 percent</p><p></p><p>Application of the original IPI to this same group of patients confirmed that the NCCN-IPI provided greater discrimination between risk groups. Whereas the five-year survival rates ranged from 43 to 84 percent with the original IPI, the NCCN-IPI rates ranged from 38 to 96 percent.</p><p class="headingAnchor" id="H3505001053"><span class="h2">Other IPI variants</span></p><p class="headingAnchor" id="H2376347898"><span class="h3">Age-adjusted IPI</span><span class="headingEndMark"> — </span>An age-adjusted IPI was evaluated for the 1274 patients ≤60 years of age in the original study group [<a href="#rid5">5</a>]. For this score, all of the prognostic factors listed above, with the exception of age and number of extranodal sites, were given one point, for a score ranging from zero to three  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a>), representing increased degrees of risk:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk – Age-adjusted IPI score of zero</p><p class="bulletIndent1"><span class="glyph">●</span>Low-intermediate risk – Age-adjusted IPI score of one</p><p class="bulletIndent1"><span class="glyph">●</span>High-intermediate risk – Age-adjusted IPI score of two</p><p class="bulletIndent1"><span class="glyph">●</span>High risk – Age-adjusted IPI score of three</p><p></p><p>Five-year OS rates for patients ≤60 with age-adjusted scores of zero, one, two, and three were 83, 69, 46, and 32 percent, respectively. Five-year OS rates for those &gt;60 with the same scores were 56, 44, 37, and 21 percent, respectively.</p><p class="headingAnchor" id="H444118441"><span class="h3">Stage-adjusted IPI</span><span class="headingEndMark"> — </span>Modifications of the IPI have been made for patients with stage I or II aggressive non-Hodgkin lymphoma ("stage-adjusted" or "stage-modified" IPI) [<a href="#rid11">11,12</a>], since there are marked differences in prognosis among such patients. In one proposed scoring system, one point was given for each of the following pretreatment variables:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;60</p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum LDH levels</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II or stage IIE disease  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Performance status ≥2  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a>)</p><p></p><p>As an example of the variability in prognosis among patients with stage I or II aggressive non-Hodgkin lymphoma undergoing similar treatment (ie, three courses of doxorubicin-containing chemotherapy plus involved region radiation therapy), patients with scores on the stage-modified IPI from zero to four had the following 10-year OS rates [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Score zero – 90 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score one or two – 56 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Score three or four – 48 percent</p><p></p><p>The prognostic utility of this stage-modified IPI has also been shown for primary gastric and intestinal diffuse large B cell lymphoma [<a href="#rid14">14,15</a>]. It has been further noted that patients with bulky stage II aggressive non-Hodgkin lymphoma have an estimated five-year OS of 49 percent, similar to that of patients with stage III or IV disease [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Gastric lymphoma'</a> and  <a class="medical medical_review" href="/d/html/4710.html" rel="external">"Treatment of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)"</a>.)</p><p class="headingAnchor" id="H14049196"><span class="h1">MOLECULAR GENETICS</span></p><p class="headingAnchor" id="H849415584"><span class="h2">Cell of origin studies</span><span class="headingEndMark"> — </span>We suggest that all cases of DLBCL undergo testing to determine the cell of origin. Gene expression profiling (GEP) is the gold standard for determining cell of origin, but has historically been performed on RNA obtained from fresh frozen tissues and is not routinely available in practice. Given their ease of use, immunohistochemistry algorithms (eg, Tally and Hans)  (<a class="graphic graphic_figure graphicRef104767" href="/d/graphic/104767.html" rel="external">figure 2</a>) are the most commonly used methods; concordance with GEP is approximately 80 percent. A focused gene expression profiling test (Lymph2Cx) can be performed on formalin-fixed paraffin-embedded tissue and is highly concordant (&gt;95 percent) with conventional GEP using RNA from unfixed cells (eg, Affymetrix gene chip) [<a href="#rid17">17</a>]. Lymph2Cx has the potential to replace immunohistochemistry algorithms for cell of origin assignment in DLBCL, but it is not yet widely available.</p><p class="headingAnchor" id="H17219052"><span class="h3">Gene expression profiling</span><span class="headingEndMark"> — </span>GEP by means of complementary DNA microarrays ("Lymphochip" microarrays) is an evolving approach to classification and diagnosis of non-Hodgkin lymphoma and other malignancies. DLBCL is a heterogeneous group of tumors that are diverse in terms of their underlying molecular pathogenesis and their clinical outcome. A number of studies have subclassified DLBCL based on GEP [<a href="#rid18">18-28</a>]. Several different classifications have been generated; the most widely used separates DLBCL into two major groups  (<a class="graphic graphic_figure graphicRef104829" href="/d/graphic/104829.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Germinal center B cell type (GCB) – These cases have a GEP that resembles a normal germinal center B cell. GCB tumors demonstrate t(14;18) translocations in approximately 30 to 40 percent of cases and a have a superior rate of five-year survival with standard R-CHOP therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated B cell type (ABC) – These cases have a GEP that resembles an activated B cell. These tumors are likely derived from a post-germinal-center B cell that has commenced early stages of plasmacytic differentiation. ABC tumors frequently demonstrate trisomy 3, deletion of <em>CDKN2A</em>, which encodes INK4A/ARF, and constitutive activation of the anti-apoptotic nuclear factor kappa B (NF-kB) pathway, and only rarely have t(14;18) translocations. When compared with GCB tumors, ABC tumors are associated with inferior rates of five-year survival following standard R-CHOP.</p><p></p><p>The GEP methods used evaluate the expression of 14 or 27 genes and use algorithms to produce a linear predictor score. The score has an assigned probability of identifying the case as ABC-type. If the probability of being ABC-type is &gt;90 percent or &lt;10 percent, cases are labeled ABC or GCB, respectively. Approximately 10 to 15 percent of cases do not meet these criteria and are identified as "unclassifiable." The role that GEP plays in the diagnosis and treatment of DLBCL is being refined. It is clear that these two subgroups have different underlying pathogenic mutations (discussed below) and different outcomes with standard R-CHOP therapy.</p><p>Additional profiling studies suggest that signatures of the surrounding stromal-cells also influence outcome [<a href="#rid29">29,30</a>]; while an area of active research, clinically actionable methods of assessing and quantifying host immune response in the DLBCL microenvironment are not yet available.</p><p class="headingAnchor" id="H849415543"><span class="h3">Hans and Tally methods</span><span class="headingEndMark"> — </span>GEP is the gold standard for determining cell of origin, but current methods are not routinely available in practice. In an effort to avoid the need for GEP, panels of immunohistochemical markers have been proposed as an alternative means to identify the GCB and ABC subtypes of DLBCL [<a href="#rid31">31</a>]. No single immunohistochemical marker can differentiate between GCB and ABC subtypes, and immunohistochemistry-based methods therefore rely on the differential expression of multiple protein markers in the GCB and ABC subtypes. The two most popular methods are the Hans algorithm and the Tally method  (<a class="graphic graphic_figure graphicRef104767" href="/d/graphic/104767.html" rel="external">figure 2</a>) [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hans algorithm</strong> – The Hans classifier uses CD10, BCL6, and MUM1 in a stepwise progression [<a href="#rid22">22</a>]. Cases that express CD10 are classified as GCB. Those that do not express CD10 are evaluated for BCL6 and, if negative, are classified as non-GCB. For those that express BCL6, MUM1 is used as a "tie-breaker." If positive, the cases are classified as non-GCB. If negative, they are classified as GCB. In the initial report, the Hans algorithm correctly assigned 112 of 142 tumors (79 percent concordance). Subsequent reports have estimated the sensitivity (85 to 90 percent), specificity (52 to 82 percent), positive predictive value (55 to 82 percent), and negative predictive value (83 to 90 percent) when compared with GEP [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tally method</strong> – The Tally method uses immunohistochemical markers to calculate a GCB score (CD10 and GCET1) and ABC score (MUM1 and FOXP1). Cases are classified as GCB or ABC if their GCB or ABC scores are greater, respectively. If the scores are equal, LMO2 is used as a "tie-breaker." If LMO2 is &lt;30 percent, the case is classified as ABC. Otherwise, the case is GCB. An initial concordance of 93 percent was reported. Subsequent reports have estimated the sensitivity (80 to 99 percent), specificity (54 to 86 percent), positive predictive value (55 to 87 percent), and negative predictive value (79 to 99 percent) when compared with GEP [<a href="#rid32">32</a>].</p><p></p><p>Limitations of these methods include a reliance on markers that are not simply called "positive" or "negative," but which require the use of staining cutoffs (eg, &gt;30 percent of cells positive). Because immunohistochemistry methods are not standardized across pathology departments, it may be difficult to use algorithms that rely on staining cutoffs in routine clinical practice, particularly at referral centers where cases and tissue blocks from multiple hospitals are seen in consultation.</p><p class="headingAnchor" id="H849415629"><span class="h3">Lymph2Cx platform</span><span class="headingEndMark"> — </span>An alternative approach is the use of technologies that precisely quantify RNA transcript levels in formalin-fixed paraffin-embedded tissue sections. These technologies, which essentially permit transcripts to be counted, appear to be less sensitive to variations in tissue fixation and processing than immunohistochemistry, and correlate well with results obtained by GEP on gene chips [<a href="#rid33">33</a>]. The Lymph2Cx is an example of a digital gene expression test that is highly concordant with other methods of GEP.</p><p>An analysis of 344 patients with de novo DLBCL treated with R-CHOP reported the following estimated outcomes at five years according to molecular subtype as defined by Lymph2Cx [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>GCB-type DLBCL – Freedom from progression (FFP) 76 percent; progression-free survival (PFS) 73 percent; disease-specific survival (DSS) 82 percent; overall survival (OS) 78 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ABC-type DLBCL – FFP 51 percent; PFS 48 percent; DSS 61 percent; OS 56 percent</p><p></p><p>These results suggest that the Lymph2Cx is able to distinguish two prognostically distinct groups of DLBCL. When widely available, Lymph2Cx will likely replace immunohistochemistry algorithms and GEP for cell of origin assignment in DLBCL since it is more reliable than immunohistochemistry and more practical than GEP methods that require fresh, unfixed tissue.</p><p class="headingAnchor" id="H2685533136"><span class="h2">MYC, BCL2, BCL6 abnormalities</span><span class="headingEndMark"> — </span>The most common cytogenetic abnormalities in DLBCL involve <em>MYC</em>, <em>BCL6</em>, and <em>BCL2.</em></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MYC</em></strong> – <em>MYC</em> is located at 8q24.21. Translocations involving <em>MYC</em> are seen in 5 to 15 percent of cases of DLBCL and confer a worse prognosis following treatment with doxorubicin-based combination chemotherapy (eg, R-CHOP) [<a href="#rid34">34-36</a>]. One series reported that inferior outcomes are primarily associated with cases in which <em>MYC</em> rearrangement involves immunoglobulin genes rather than other partner genes [<a href="#rid37">37</a>]. <em>MYC</em> amplification occurs in 2 percent of DLBCL and may also be associated with worse outcomes [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BCL6</em></strong><strong> </strong>– <em>BCL6</em> is located at 3q27.3. <em>BCL6</em> translocations are found in up to one-third of DLBCL. There is a trend toward association with the ABC subtype, but the presence of this genetic aberration does not appear to have independent prognostic value [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BCL2</em></strong> – <em>BCL2</em> is located at 18q21.33. <em>BCL2</em> translocations are found in approximately one-third of DLBCL, mostly in the GCB molecular subtype. Translocations involving <em>BCL2</em> do not appear to impact survival when present as the sole genetic abnormality (eg, not associated with concurrent <em>MYC</em> translocation) [<a href="#rid40">40,41</a>]. Expression of BCL2 protein in DLBCL does not correlate with the t(14;18). While the ABC subtype of DLBCL only rarely has the t(14;18), amplifications of 18q21 are seen in up to two-thirds of cases, providing a possible mechanism for <em>BCL2</em> overexpression in these tumors. The impact of BCL2 protein expression on clinical outcomes is controversial [<a href="#rid41">41,42</a>], and additional studies are needed to clarify the prognostic impact of BCL2 expression in different subtypes of DLBCL.</p><p></p><p class="headingAnchor" id="H431287426"><span class="h3">Double hit lymphoma</span><span class="headingEndMark"> — </span>The term double hit lymphoma is sometimes used colloquially to refer to cases of lymphoma that morphologically resemble DLBCL, but contain translocations of the <em>MYC</em> gene together with rearrangement of <em>BCL2</em> and/or <em>BCL6</em>. This is no longer considered a type of DLBCL; in the 2016 World Health Organization (WHO) classification, double hit DLBCL was classified as high-grade B cell lymphoma, with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> rearrangements [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma"</a>.)</p><p>When treated with R-CHOP chemotherapy, double hit lymphomas have a worse prognosis than DLBCL  (<a class="graphic graphic_figure graphicRef104828" href="/d/graphic/104828.html" rel="external">figure 4</a>) [<a href="#rid36">36,44-46</a>]. Rare triple hit tumors with <em>MYC, BCL2, </em>and<em> BCL6</em> rearrangements have also been described, and most data suggest that these genotypes are also associated with poor clinical outcomes [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H431287440"><span class="h3">Double expressor lymphoma</span><span class="headingEndMark"> — </span>While all DLBCL with <em>MYC</em> translocation demonstrate increased MYC expression, some tumors have overexpression of MYC due to other mechanisms (eg, gene amplification). Overexpression of MYC and BCL2 can be identified with immunohistochemistry.</p><p>In several independent studies, co-expression of MYC and BCL2 was seen in 20 to 30 percent of cases of DLBCL and predicted a lower complete response rate and shorter PFS and OS [<a href="#rid44">44,45,47</a>]. Furthermore, in an analysis of 893 patients with de novo DLBCL treated with R-CHOP, multivariate analysis demonstrated that co-expression of MYC/BCL2 was associated with inferior OS (hazard ratio [HR] 2.52; 95% CI 1.73-3.67) and PFS (HR 2.45; 95% CI 1.71-3.51) [<a href="#rid46">46</a>]. However, while the presence of a <em>MYC</em> translocation conferred a poor prognosis independent of <em>BCL2</em>, MYC protein expression was only associated with worse outcome when accompanied by BCL2 expression.</p><p>Further studies are needed to clarify the prognosis of lymphomas that overexpress BCL2 and MYC based on immunohistochemistry. Cases with MYC overexpression identified by immunohistochemistry should undergo genetic testing for <em>MYC</em> translocations. Furthermore, since double hit DLBCLs have a particularly poor prognosis, testing for <em>BCL2 </em>and<em> BCL6</em> rearrangements should also be considered in cases exhibiting high levels of MYC protein expression.</p><p class="headingAnchor" id="H22283576"><span class="h2">Identifying molecular subtype</span><span class="headingEndMark"> — </span>In order to subtype DLBCL and to avoid misclassifying as DLBCL cases of high-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> gene rearrangements, we suggest the following tests to assess molecular risk in all lymphomas that have the morphologic features of DLBCL:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of </strong><strong><em>MYC</em></strong><strong>,</strong><strong><em> BCL2</em></strong><strong>, and </strong><strong><em>BCL6</em></strong><strong> gene</strong> <strong>status</strong> by fluorescence in situ hybridization (FISH) or cytogenetics. An acceptable alternative is to perform immunohistochemistry for MYC and BCL2; cases with MYC overexpression on immunohistochemistry should have further testing for <em>MYC, BCL2, </em>and<em> BCL6</em> gene rearrangements by FISH. Our approach is to perform <em>MYC</em> FISH studies only when MYC staining is positive in &gt;40 percent of tumor cell nuclei.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of cell of origin</strong> by GEP analysis, immunohistochemistry algorithms, or Lymph2Cx platform. Given their ease of use, immunohistochemistry algorithms (eg, Tally and Hans)  (<a class="graphic graphic_figure graphicRef104767" href="/d/graphic/104767.html" rel="external">figure 2</a>) are the most commonly used method; concordance with GEP is approximately 80 percent. While not yet widely available, the Lymph2Cx can be performed on formalin-fixed paraffin-embedded tissue and is highly concordant with other methods of GEP that require fresh, unfixed tissue. When available, Lymph2Cx may replace immunohistochemistry algorithms for cell of origin assignment in DLBCL.</p><p></p><p>Using this information, a lymphoma with DLBCL morphology may be subclassified as one of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Germinal center B cell (GCB) DLBCL</strong> – Cases of GCB DLBCL (as defined by GEP, immunohistochemistry algorithms, or Lymph2Cx) have a relatively good prognosis following standard therapy with R-CHOP. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated B cell (ABC) DLBCL or non-GCB DLBCL</strong> – Cases with non-GCB DLBCL (identified by conventional GEP, immunohistochemistry algorithms, or Lymph2Cx) have high relapse rates and a less favorable prognosis following treatment with R-CHOP.</p><p></p><p class="headingAnchor" id="H4290212309"><span class="h2">Deep sequencing</span><span class="headingEndMark"> — </span>Deep sequencing of DLBCL genomic DNA has confirmed that heterogeneity in DLBCL extends to the tumor cell genome [<a href="#rid48">48-50</a>]. Studies that included nearly 2000 cases of DLBCL identified driver mutations that may identify genetically distinct subtypes of GCB and non-GCB DLBCL, with different clinical outcomes following standard therapy [<a href="#rid51">51-53</a>]. These observations must be confirmed before genomic testing is used to stratify patients and select therapy.</p><p class="headingAnchor" id="H2982404884"><span class="h2">Cell-free plasma DNA</span><span class="headingEndMark"> — </span>Circulating cell-free DNA can be quantified in plasma by next-generation sequencing of IgH gene segments derived from DLBCL [<a href="#rid54">54-56</a>]. In initial studies, tumor DNA load was reported to correlate with imaging-based tumor stage and to be a sensitive predictor of disease relapse. This modality requires further evaluation before using it clinically to assess disease burden and response to therapy.</p><p class="headingAnchor" id="H17221149"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (approximately one-quarter of cases). DLBCL is morphologically, genetically, biologically, and prognostically heterogeneous. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors</strong> – Outcomes are associated with both clinical features and pathologic aspects of DLBCL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Any of the following<strong> </strong>tools can be used to estimate prognosis for patients with DLBCL:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>International Prognostic Index (IPI)</strong> – The IPI  (<a class="graphic graphic_table graphicRef70850" href="/d/graphic/70850.html" rel="external">table 1</a>) uses age, performance status  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 2</a>), serum lactate dehydrogenase (LDH), disease stage  (<a class="graphic graphic_table graphicRef97479" href="/d/graphic/97479.html" rel="external">table 3</a>), and number of extranodal sites to define prognostic categories. The IPI distinguishes two prognostic groups among patients treated with standard therapy (R-CHOP; <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>), although it defined four groups in the pre-rituximab era. (See <a class="local">'International Prognostic Index'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Revised IPI</strong> – The revised IPI (R-IPI) uses the same risk factors and scoring system as the IPI, but it assigns patients to three risk groups.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>National Comprehensive Cancer Network (NCCN)-IPI</strong> – The NCCN-IPI uses the same clinical variables, but age and LDH are considered as continuous, rather than dichotomous, variables and the location of extranodal disease is used rather than the number of extranodal sites. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic features </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mutations</strong> – Evaluation of MYC, BCL2, and BCL6 expression or mutation is used to exclude certain lymphomas that resemble DLBCL (eg, so-called “double-hit” lymphoma, which is no longer considered a DLBCL category) and may affect treatment prognosis or treatment. (See <a class="local">'MYC, BCL2, BCL6 abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cell of origin status</strong> – Cell of origin (COO) studies using immunohistochemistry algorithms (eg, Tally and Hans)  (<a class="graphic graphic_figure graphicRef104767" href="/d/graphic/104767.html" rel="external">figure 2</a>) or molecular methods may predict responsiveness to therapy. (See <a class="local">'Cell of origin studies'</a> above.)</p><p></p><p class="bulletIndent2">There are two major COO subtypes: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Germinal center B cell type (GCB)</strong> – Malignant cells resemble normal germinal center B cells and have more favorable outcomes with standard chemoimmunotherapy  (<a class="graphic graphic_figure graphicRef104829" href="/d/graphic/104829.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Non-GCB or</strong> <strong>activated B cell type (ABC)</strong> – Malignant cells resemble activated B cells and are associated with inferior outcomes.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Smith A, Crouch S, Howell D, et al. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma. Cancer Epidemiol 2015; 39:1103.</a></li><li><a class="nounderline abstract_t">Kallam A, Armitage JO, Chen B, et al. Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL). Blood 2016; 128:5949.</a></li><li><a class="nounderline abstract_t">International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987.</a></li><li><a class="nounderline abstract_t">Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:2373.</a></li><li><a class="nounderline abstract_t">Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117:7070.</a></li><li><a class="nounderline abstract_t">Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109:1857.</a></li><li><a class="nounderline abstract_t">Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010; 21:1486.</a></li><li><a class="nounderline abstract_t">Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123:837.</a></li><li><a class="nounderline abstract_t">Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21.</a></li><li><a class="nounderline abstract_t">Møller MB, Pedersen NT, Christensen BE. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. Am J Hematol 2003; 74:94.</a></li><li><a class="nounderline abstract_t">Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002; 20:197.</a></li><li><a class="nounderline abstract_t">Cortelazzo S, Rossi A, Roggero F, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 1999; 10:1433.</a></li><li><a class="nounderline abstract_t">Cortelazzo S, Rossi A, Oldani E, et al. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol 2002; 118:218.</a></li><li><a class="nounderline abstract_t">Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004; 22:2982.</a></li><li><a class="nounderline abstract_t">Scott DW, Mottok A, Ennishi D, et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol 2015; 33:2848.</a></li><li><a class="nounderline abstract_t">Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503.</a></li><li><a class="nounderline abstract_t">Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68.</a></li><li><a class="nounderline abstract_t">Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937.</a></li><li><a class="nounderline abstract_t">Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777.</a></li><li><a class="nounderline abstract_t">Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275.</a></li><li><a class="nounderline abstract_t">Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99:1136.</a></li><li><a class="nounderline abstract_t">Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111:5509.</a></li><li><a class="nounderline abstract_t">Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26:4587.</a></li><li><a class="nounderline abstract_t">Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117:4836.</a></li><li><a class="nounderline abstract_t">Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011; 118:1350.</a></li><li><a class="nounderline abstract_t">Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29:4079.</a></li><li><a class="nounderline abstract_t">Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313.</a></li><li><a class="nounderline abstract_t">Perry AM, Cardesa-Salzmann TM, Meyer PN, et al. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood 2012; 120:2290.</a></li><li><a class="nounderline abstract_t">Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15:5494.</a></li><li><a class="nounderline abstract_t">Scott DW. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic? Am Soc Clin Oncol Educ Book 2015; :e458.</a></li><li><a class="nounderline abstract_t">Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123:1214.</a></li><li><a class="nounderline abstract_t">Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114:3533.</a></li><li><a class="nounderline abstract_t">Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28:3360.</a></li><li><a class="nounderline abstract_t">Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121:2253.</a></li><li><a class="nounderline abstract_t">Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood 2015; 126:2466.</a></li><li><a class="nounderline abstract_t">Valera A, López-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98:1554.</a></li><li><a class="nounderline abstract_t">Shustik J, Han G, Farinha P, et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica 2010; 95:96.</a></li><li><a class="nounderline abstract_t">Papakonstantinou G, Verbeke C, Hastka J, et al. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113:383.</a></li><li><a class="nounderline abstract_t">Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011; 17:7785.</a></li><li><a class="nounderline abstract_t">Petrella T, Copie-Bergman C, Brière J, et al. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. Ann Oncol 2017.</a></li><li><a class="nounderline abstract_t">Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.</a></li><li><a class="nounderline abstract_t">Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3452.</a></li><li><a class="nounderline abstract_t">Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3460.</a></li><li><a class="nounderline abstract_t">Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013; 121:4021.</a></li><li><a class="nounderline abstract_t">Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016; 127:2182.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189.</a></li><li><a class="nounderline abstract_t">Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.</a></li><li><a class="nounderline abstract_t">Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109:3879.</a></li><li><a class="nounderline abstract_t">Reddy A, Zhang J, Davis NS, et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell 2017; 171:481.</a></li><li><a class="nounderline abstract_t">Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 2018; 378:1396.</a></li><li><a class="nounderline abstract_t">Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24:679.</a></li><li><a class="nounderline abstract_t">Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015; 125:3679.</a></li><li><a class="nounderline abstract_t">Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2013; 163:123.</a></li><li><a class="nounderline abstract_t">Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015; 16:541.</a></li></ol></div><div id="topicVersionRevision">Topic 83821 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150940" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150940" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341588" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Center Effect and Socioeconomic Determinants of Overall Survival (OS) of Diffuse Large B Cell Lymphoma (DLBCL)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8141877" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A predictive model for aggressive non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385988" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536860" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105812" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19920060" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24264230" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647875" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14508794" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773170" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643533" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100151" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210737" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The limits of limited stage lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240231" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676951" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786909" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12075054" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12724484" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular diagnosis of the hematologic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504078" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830458" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445689" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18662967" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21441466" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670469" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947824" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038878" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Stromal gene signatures in large-B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22740447" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706817" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25993210" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398326" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704118" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498406" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23335369" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26373676" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716551" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797725" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380403" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21933893" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28327893" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851565" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665537" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449635" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26834242" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21390126" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Inactivating mutations of acetyltransferase genes in B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796119" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22343534" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28985567" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29641966" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29713087" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887775" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23795711" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25842160" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
